Podcast Episodes

Zeiss MEL 90 Approved by FDA

Zeiss receives a major approval for its new excimer laser;

Bausch + Lomb makes two deals to bolster its pipeline in glaucoma and geographic atrophy; a…

1 year, 4 months ago

Special Report – Increasing Access to Care Through the Cure Blindness Project

Leaders from Cure Blindness Project discuss efforts to restore vision and prevent avoidable blindness in underserved communities around the world.

Le…

1 year, 4 months ago

Glaukos Submits NDA for Epi-On CLX Candidate

Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for …

1 year, 4 months ago

2024 Year in Review — Part 2

In today’s episode, we review the top stories from the second half of 2024. The last six months saw the launch of first-of-its-kind IOLS; the clinica…

1 year, 5 months ago

2024 Year in Review — Part 1

In today’s broadcast, we look back at the top stories from the first half of 2024. There were several advancements made during the first six months.,…

1 year, 5 months ago

B+L Bolsters Glaucoma Offerings with Elios Acquisition

Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a m…

1 year, 5 months ago

Phase 3 Results for Novel Sedation Tablet

New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and O…

1 year, 5 months ago

Phakic IOL for Presbyopia Approved in Europe

A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL Injection System internationally; and the FDA cleared a…

1 year, 5 months ago

Special Report: OWL Celebrates 20th Anniversary

Executives from Ophthalmic World Leaders discuss the history and goals of thee organization as it celebrates its 20th anniversary. 

Learn more about …

1 year, 6 months ago

Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD

The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye dise…

1 year, 6 months ago